Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,824 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: B: Placebo Clear all
Active, not recruiting Phase 3 Interventional

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 63 Years
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
132
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults

NCT05908825
View directory record Official record
Conditions
Photodamaged Skin
Interventions
Vitamin C with AHA Exfoliative Serum, Placebo serum
Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
30 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

NCT00466440
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin, placebo, docetaxel, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 6, 2026, 9:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

NCT06657768
View directory record Official record
Conditions
Alzheimer Disease, Healthy
Interventions
LY4006895, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
11
States / cities
Los Alamitos, California • Lady Lake, Florida • Maitland, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

NCT01783821
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
Budesonide, Placebo, Formoterol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Tucson, Arizona • Stanford, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

NCT02175121
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Placebo, PF-06291874
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

NCT06673238
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-722, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Cypress, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)

NCT06625840
View directory record Official record
Conditions
Healthy
Interventions
MK-1167, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT06790121
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
23
States / cities
Encino, California • Sacramento, California • Thousand Oaks, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

NCT02565914
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 6, 2026, 9:41 PM EDT
Terminated Phase 2 Interventional Results available

Vitamin B12a Vasoplegic Syndrome

NCT03735316
View directory record Official record
Conditions
Vasoplegic Syndrome
Interventions
Hydroxocobalamin, Cardiopulmonary Bypass, Placebos
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 6, 2026, 9:41 PM EDT
Terminated Phase 1 Interventional Results available

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)

NCT06768658
View directory record Official record
Conditions
Nausea and Vomitting
Interventions
TAK-951, TAK-951 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Misoprostol for Non-Viable Pregnancies

NCT00426491
View directory record Official record
Conditions
Abortifacient Agents, Nonsteroidal, Abortion, Incomplete, Misoprostol, Pregnancy
Interventions
Misoprostol
Drug
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2006
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2008 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection

NCT01079806
View directory record Official record
Conditions
Chronic Hepatitis B Virus, Pediatric
Interventions
Entecavir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
15
States / cities
San Francisco, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958
View directory record Official record
Conditions
Treatment Resistant Depressive Disorder
Interventions
Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 64 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

NCT01596725
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 6, 2026, 9:41 PM EDT
Terminated Phase 2 Interventional Results available

Neurotropin to Treat Chronic Neuropathic Pain

NCT00006289
View directory record Official record
Conditions
Complex Regional Pain Syndrome Type I, Complex Regional Pain Syndrome Type II
Interventions
Placebo, Neurotropin
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Duration of Effect of Acidform Gel on Vaginal pH

NCT02693418
View directory record Official record
Conditions
Healthy
Interventions
Acidform 5 g, Placebo 4 g, Acidform 4 g, Acidform 3 g
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 6, 2026, 9:41 PM EDT
Recruiting Phase 2 Interventional

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

NCT07225621
View directory record Official record
Conditions
Glioblastoma, GBM
Interventions
5-ALA HCl + LIDU SDT, Placebo + Sham SDT
Combination Product
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Boston, Massachusetts • Rochester, Minnesota • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 6, 2026, 9:41 PM EDT
Withdrawn Phase 2 Interventional

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

NCT02500784
View directory record Official record
Conditions
Alzheimer's Disease, Cognitive Dysfunction
Interventions
Formoterol A, Formoterol B (placebo)
Drug · Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery

NCT02689258
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
8
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of PRAX-944 in Participants With Essential Tremor

NCT05021978
View directory record Official record
Conditions
Essential Tremor
Interventions
Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944, Part B: 120 mg PRAX-944 and Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Port Charlotte, Florida • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
59
States / cities
Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 6, 2026, 9:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 6, 2026, 9:41 PM EDT